Advanced Search

 

Study ID Status Title Patient Level Data
205787 Completed Assessment of Patients Treated with Albiglutide - Phase 1
205795 Completed Sun Protection Factor Determination (In vivo determination of the sun protection factor ISO 24444:2010(E))
205808 Completed A double-blind, randomized, placebo controlled, dose escalating crossover study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in Japanese healthy male volunteers
205865 Completed Sun Protection Factor Determination: In vivo Determination of the Sun Protection Factor (SPF): ISO 24444:2010(E)
205915 Completed A Clinical Study to Evaluate the Ability of an Experimental Denture Adhesive to Prevent Food Particle Ingress Under Dentures
206 Completed Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers
206251 Completed A Human Subject 24 Hour Patch Test to Assess the Irritation Potential of Four Skin Balm Products
206350 Completed Description of QoL data (SF-36 and FACIT) from the BLISS long-term extension study
206707 Completed Indirect treatment comparison of ropinirole and pramipexole for management of symptoms in patients with advanced Parkinson’s disease
206822 Completed PGx7659: Exploratory Pharmacogenetic Investigation of Efficacy Response to Relvar/Breo in Asthma studies 106827, 106829, 106837, 113091 and 116863
206823 Completed PGx7660: Exploratory Pharmacogenetic Investigation of Efficacy Response to Relvar/Breo in Phase III COPD studies 112206, 112207, 113108, and 200820
207 Completed A bioequivalence study of 50, 100, and 150 mg bupropion sustained-release tablets in healthy male volunteers
207266/084 Completed A Study to Assess the Effect of Repeat Dose NCE on the Steady-State Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects
207267 Not yet recruiting Assessment of Patients Treated with Albiglutide – Phase 2
207499/039 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/040 Completed A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/041 Completed A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/042 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/076 Completed A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/091 Completed A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/110 Completed A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
207499/111 Completed A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease
207499/121 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
207499/125 Completed A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/156 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.